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ABSTRACT
Poly(ADP-ribose) polymerases (PARPs) facilitate the
repair of DNA single-strand breaks (SSBs). When
PARPs are inhibited, unrepaired SSBs colliding with
replication forks give rise to cytotoxic double-strand
breaks. These are normally rescued by homologous
recombination (HR), but, in cells with suboptimal HR,
PARP inhibition leads to genomic instability and cell
death, a phenomenon currently exploited in the ther-
apy of ovarian cancers in BRCA1/2 mutation carri-
ers. In spite of their promise, resistance to PARP in-
hibitors (PARPis) has already emerged. In order to
identify the possible underlying causes of the resis-
tance, we set out to identify the endogenous source
of DNA damage that activates PARPs. We argued that
if the toxicity of PARPis is indeed caused by unre-
paired SSBs, these breaks must arise spontaneously,
because PARPis are used as single agents. We now
show that a significant contributor to PARPi toxi-
city is oxygen metabolism. While BRCA1-depleted
or -mutated cells were hypersensitive to the clini-
cally approved PARPi olaparib, its toxicity was sig-
nificantly attenuated by depletion of OGG1 or MYH
DNA glycosylases, as well as by treatment with re-
active oxygen species scavengers, growth under hy-
poxic conditions or chemical OGG1 inhibition. Thus,
clinical resistance to PARPi therapy may emerge sim-
ply through reduced efficiency of oxidative damage
repair.
INTRODUCTION
The seminal discovery of synthetic lethality between defec-
tive homologous recombination (HR) and chemical inhibi-
tion of poly(ADP-ribose) polymerases (PARPs) led to the
development of clinical PARP inhibitors (PARPis) that rep-
resent a significant breakthrough in the therapy of famil-
ial breast and ovarian cancers linked to mutations in the
BRCA1/2 genes (1–3). The cascade of events leading to syn-
thetic lethality is widely believed to be triggered by single-
strand breaks (SSBs). In healthy cells, SSBs rapidly acti-
vate PARPs, which help facilitate break repair (4,5). Un-
repaired SSBs that persist until S phase collide with repli-
cation forks to give rise to one-ended double-strand breaks
(DSBs), but these can be rescued by HR (6,7). Chemically-
inhibited PARPs remain bound at the SSBs and inhibit their
repair (8–10), which increases the number of toxic DSBs.
While normal cells can cope with this increase, DSB accu-
mulation in cells with suboptimal HR, such as those carry-
ing BRCA1/2 mutations, leads to genomic instability and
cell death.
The PARPis olaparib, rucaparib, niraparib, talazoparib
or veliparib are currently used in the therapy of HR-
deficient cancers (11–13). Their efficacy in the treatment of
several different types of cancers is currently being tested
in a large number of clinical trials, but their current indi-
cation is as fourth line therapy of primarily ovarian can-
cers in patients with BRCA1/2 mutations who have re-
sponded to platinum treatment. Although the emergence
of PARPis represents a major breakthrough in cancer ther-
apy, drug resistance has already emerged. This can have
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several causes: drug efflux through upregulation of mul-
tiple drug resistance pathways, partial restoration of HR
through secondary mutations in the BRCA loci, or inacti-
vation of non-homologous end-joining (NHEJ) pathways
that cause genomic instability in HR-deficient cells through
error-prone processing of unrepaired DSBs (14–18). How-
ever, many cases of resistance are apparently not linked to
the above. In an attempt to identify alternative modes of
PARPi resistance, we first wanted to elucidate the underly-
ing cause(s) of PARPi cytotoxicity.
We argued that if PARPi toxicity is indeed linked to
immobilization of PARPs on SSBs, the breaks must arise
spontaneously, because PARPis are used as single agents,
rather than in combination with genotoxic substances.
However, there are several sources of SSBs in genomic
DNA, ranging from aborted adenylated ligation intermedi-
ates or type I topoisomerase adducts, gaps betweenOkazaki
fragments and nicks generated by RNases during excision
of ribonucleotides from DNA, to cleaved abasic sites re-
sulting from spontaneous base loss or through the removal
of aberrant bases by base excision repair (BER) (19). We
wanted to learn whether all SSBs contribute equally to
PARPi toxicity, or whether there is a subset of breaks, the
repair of which is particularly dependent on PARPs.
In this study, we focussed on SSBs associated with BER.
Hydrolysis and oxidation ofDNAbases represent the great-
est and unavoidable threats to genomic integrity. Dur-
ing BER (4), the aberrant bases are excised by one of
several specialized DNA glycosylases (MDB4, SMUG1,
TDGandUNG2,MYH (MUTYH),NEIL1/2/3,NTHL1,
OGG1/2) to leave behind abasic (apurinic/apyrimidinic,
AP) sites, which are subsequently cleaved either by AP-
endonucleases (APE1/2) or by the intrinsic lyase activity
of the glycosylases. Because oxidation represents the most
abundant source of aberrant bases in DNA (20), we asked
whether SBBs generated during the processing of oxidative
DNA damage contribute to PARPi cytotoxicity.
DNA oxidation gives rise to a large spectrum of aber-
rant bases [8-oxoguanine, 8-oxoadenine, formamidopyrimi-
dine, thymine glycol, hydroxymethylcytosine andmany oth-
ers (21)] in nuclear and mitochondrial DNA of all organ-
isms (20). The consequences of the presence of these modi-
fied or fragmented bases in DNA have been studied in some
detail, with early investigations focussing primarily on their
mutagenicity. These studies revealed that of all the differ-
ent structures, Go (8-oxoguanine) was the most deleterious.
Indeed, Escherichia coli in which the three genes encoding
enzymes involved inGo processing (fpg/mutM,micA/mutY
and mutT) have been disrupted display one of the strongest
knownmutator phenotypes (22). In eukaryotes, Go process-
ing is catalysed primarily by theMutMorthologOGG1, the
MutY homolog MYH (MUTYH) and the MutT homolog
MTH1 as indicated in Figure 1. As in E. coli, disruption of
the three genes encoding these enzymes in mouse resulted
in a 37 times higher mutation rate compared to wild-type
animals. Importantly, G to T transversions––a hallmark of
non-repair of Go/A mispairs––represented 96% of muta-
tions (23) and this phenotype is reflected in the tumours
of multiple adenomatous polyposis syndrome patients, who
carry mutations in MYH (24). The latter evidence demon-
strates the importance of Go processing by BER in muta-
Figure 1. Simplified scheme of Go processing. Oxidation of guanine by
ROS gives rise to a Go/C base pair. Removal of Go by OGG1, followed by
filling of the single nucleotide gap by BER (with the help of pol- or -) re-
stores the original G/C base pair. Go residues remaining in template DNA
strand will mispair with A during pol-/ε catalysed replication. MYH re-
moves the mispaired adenines and BER (with the help of pol- or -) in-
serts a C opposite the Go to restore a Go/C pair, which can be addressed
by OGG1/BER to restore the original G/C. If the deoxynucleotide pool
is oxidized, dGoTP should be hydrolyzed to dGoMP by MTH1. Incom-
plete dGoTP hydrolysis can result in Go being inserted opposite template
A during replication. The resulting A/Go mispair is addressed by MYH
and BER similarly to the Go/A mispair.
genesis and carcinogenesis, but we wanted to focus on its
possible role as a threat to genomic stability in the absence
of HR. As mentioned above, removal of aberrant bases by
DNA glycosylases results in the generation of abasic sites.
These intermediates are highly-reactive and can give rise to
e.g. protein/DNA cross-links. This side-reaction is largely
avoided by the rapid action of the highly abundant AP-
endonucleases, but the SSBs that are generated are not with-
out danger to processes ranging from transcription to repli-
cation. It had been postulated that these SSBs are not ‘vis-
ible’ to other pathways of DNA metabolism, because BER
has been believed to proceed by a concerted, ‘passing the
baton’ mechanism, in which the glycosylase hands over to
the AP-endonuclease, which then hands over to the poly-
merase that then passes the final intermediate to the DNA
ligase (25). We have shown earlier that this may not always
be the case, given that SSBs generated during Go processing
are visible to the mismatch repair system (26).
Here, we show that––if unrepaired––SSBs arising during
oxidative damage processing are channelled to HR and sig-
nificantly contribute to the toxicity of PARPis. Thus, while
BRCA1-depleted cells were sensitive to the clinically ap-
proved PARPi olaparib, knock-down of OGG1 or MYH
DNA glycosylases, or chemical inhibition of OGG1, re-
sulted in marked drug resistance. Moreover, the extent
of desensitization to olaparib could be augmented by the
reactive oxygen species (ROS) scavenger N-acetylcysteine
(NAC) or by growing the cells in hypoxic conditions. The
level of DNA oxidative damage and its metabolism thus
need to be added to the growing list of factors (18) affecting
the response of cells and tissues to PARPi treatment.
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MATERIALS AND METHODS
Cell culture and treatments
The A2780 (ECACC 93112519) cell line was generated
from a biopsy of an untreated ovarian cancer and was pur-
chased from ECACC. TP53 and BRCA1/2 genes are wild-
type. The cells were grown in Dulbecco’s-modified Eagle’s
medium (DMEM) (Gibco) supplemented with 5% fetal calf
serum (FCS, Gibco). HEK293 cells (ATCC) were grown
in DMEM supplemented with 10% FCS. Both media con-
tained also penicillin (100 U/ml, Gibco) and streptomycin
(100 g/ml, Gibco).
SUM149PT cells were kindly provided by Mark
O’Connor (Astra Zeneca, Cambridge, UK). This breast
cancer cell line is hemizygous for BRCA1 and the single
BRCA1 allele carries a frameshift (2288delT)mutation. The
cells were cultured in Ham’s F-12 medium supplemented
with 5% heat-inactivated FCS, 10 mMHEPES.KOH pH 8,
1 g/ml hydrocortisone and 5 g/ml insulin.
A 20 mM stock solution of olaparib (AZD2281, Ku-
0059436; S1060, Selleckchem)was prepared in dimethyl sul-
foxide (DMSO) and stored at−80◦C. For the clonogenic as-
says, the solution was diluted in DMEM and added to cells
at the indicated final concentrations. For comet assays and
immunofluorescence, the cells were treated with 1 M ola-
parib for 24 h. The OGG1-ihibitor TH5487 (27) was used
at a final concentration of 0.5 M for clonogenic assay, 1
h before olaparib treatment. NAC powder (Sigma) was dis-
solved in sterile water. A 500 mM stock solution was added
directly to the cell culturemedium to yield a final concentra-
tion of 2.5 mM (0.625 mM for SUM149PT). The cells were
treated first for 24 h, then again for 30 min prior to olaparib
treatment.
Hypoxic conditions were induced by growing the cells in
1% O2 concentration in a hypoxic chamber (Ruskinn SCI-
tive).
siRNA transfections
The cells were grown to 30–50% confluency and trans-
fected with 40 pmol siRNA oligonucleotides using Lipo-
fectamine RNAiMAX™ (Invitrogen) according to the man-
ufacturer’s instructions. The following oligonucleotides
were used: siLuciferase (siLuc): 5
′
CGUACGCGGAAUAC
UUCGA3
′
; siMYH: 5
′
GCUGACAUAUCAAGUAUAU3
′
(28); siOGG1: 5
′
UCCAAGGUGUGCGACUGCUGCG
ACA3
′
(29); siBRCA1: 5
′
ACCAUACAGCUUCAUAAA
UAA3
′
; siRAD51: 5
′
-GAGCUUGACAAACUACUUC-
3
′
; siRNaseH2: 5
′
GGACUUGGAUACUGAUUAU3
′
(by
Microsynth, Balgach, Switzerland).
Cell survival assays
Cells were seeded in triplicates in 6-well plates at a den-
sity of 300–500 cells per well 72 h after siRNA transfec-
tion. Twenty-four hours later, the cells were treated with
the indicated concentrations of olaparib and left at 37◦C.
Colony growth was interrupted after 10–14 days. The cells
were washed in phosphate-buffered saline (PBS) and incu-
bated with 0.5% Crystal violet in 20% EtOH for 15 min
at room temperature (RT). Crystal violet was removed and
gently washed away with H2O. The colonies were counted
when dry. Cell survival after the treatment was shown as
percentage of the viability of the untreated cells in a line
chart, reporting the average of three independent assays
with standard deviation and significance calculated by Two-
Way ANOVA (P-value < 0.05 *, < 0.01 **, < 0.001 ***, <
0.0001 ****).
Alkaline comet assays
The CometAssay® kit from Trevigen® was used as de-
scribed. Seventy-two hours after transfection with siRNA
cells were exposed to 1 M olaparib for 24 h. Cells were
re-suspended in ice-cold PBS at a concentration of 3 ×
105 cells/ml, embedded in molten low melting temperature
agarose at a ratio of 1:10 and spread on CometSlides™.
The slides were immersed in 4◦C Lysis Solution ON be-
fore exposure to Alkaline Unwinding Solution (300 mM
NaOH, 1 mM ethylenediaminetetraacetic acid (EDTA),
pH>13) for 1 h at 4◦C and electrophoresis in chilled Al-
kaline Electrophoresis Solution (300 mM NaOH, 1 mM
EDTA, pH>13) at 21 V for 30 min. Subsequently, the
slides were washed twice in distilled H2O, immersed in 70%
ethanol for 5 min, dried at 37◦C and stained with SYBR®
Green for 30 min. Images were captured with an Olym-
pus IX81 fluorescence microscope and at least 80 cells were
analysed in each of three independent experiments by Im-
age J software.
The analysis of the average of three independent assays
with standard deviation and significance calculated by Two-
Way ANOVA (P-value < 0.05 *, < 0.01 **, < 0.001 ***, <
0.0001 ****) was reported in a bar graph.
Immunofluorescence
Cells were seeded in 6-well plates (300 000/well) on steril-
ized coverslips 72 h after siRNA transfection. After adhe-
sion, 1 Molaparib treatment was performed for 24 h. Fix-
ation for 10 min at RT in 4% formaldehyde followed two
washings in PBS. Coverslips were washed twice again for
5 min and the cells were permeabilized in 0.3% Triton/PBS
for 5 min at RT. After two more washings, 5% bovine serum
albumin (BSA)/PBS blocking was carried out for 1 h at
RT. The primary antibody against  -H2AX (Ser139) (Merk
Millipore 05–636, Mouse) was used at a 1:250 dilution in
5% BSA/PBS for 1 h in a humidified chamber. After wash-
ing, the coverslips were incubated for 30 min with the sec-
ondary antibody AlexaFluor 488 (Invitrogen A11029, goat
anti-mouse), diluted 1:100 in 5% BSA/PBS. The coverslips
were then washed twice in PBS and once in distilled H2O,
dried and put on slides with mounting medium containing
DAPI. Images were taken with the Olympus IX81 fluores-
cencemicroscope. At least 100 cells per conditionwere anal-
ysed. The analysis of the average of three independent as-
says with standard deviation and significance calculated by
Two-Way ANOVA (P-value < 0.05 *, < 0.01 **, < 0.001
***, < 0.0001 ****) was reported in a bar graph.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tumour sections (2.5
m) were transferred to glass slides. Immunohistochem-
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istry was carried out using the automated Leica BOND
system and the Bond Polymer Refine Detection Kit (Leica
Biosystems). Go was visualized using a mouse monoclonal
8-oxoguanine primary antibody (ab64548, Abcam, diluted
1:250). The immunostained slides were scanned using the
NanoZoomer Digital Slide Scanner (Hamamatsu Photon-
ics).
RESULTS
Knock-down of OGG1 attenuates the sensitivity of BRCA1-
depleted cells to olaparib
As mentioned above, removal of modified bases by DNA
glycosylases gives rise to abasic (apurinic, apyrimidinic, AP)
sites, which are cleaved by AP-endonucleases. That cleaved
AP-sites contribute to PARPi toxicity could be shown by
the synthetic lethality between PARP inhibition and knock-
down of XRCC1 (10,30), a cofactor of DNA ligase III that
is involved in the final step of BER. However, because most
AP-sites are channelled to the XRCC1/LigIII-dependent
step, the above evidence does not provide any information
regarding their source. Moreover, XRCC1 is a scaffold pro-
tein that has several partners active in different DNA repair
pathways (31).
Because Go represents the most abundant aberrant DNA
base in both genomic andmitochondrial DNA (32), we pos-
tulated that a significant proportion of spontaneous AP-
sites is likely to originate from the processing of this aber-
rant base. The main glycosylase responsible for Go removal
is OGG1, which possesses an intrinsic DNA lyase activity.
This cleaves the 3′ side of the AP-site (33,34), such that the
subsequent cleavage at its 5′ side by the AP-endonuclease
generates a single nucleotide gap rather than a nick. We ar-
gued that the latter lesions might persist longer than simple
nicks and may thus be more readily detected by PARPs. In-
hibition or depletion of OGG1 would therefore be expected
to reduce the number of SSBs and gaps, and thus decrease
the toxicity of PARPis in HR-deficient cells.
That OGG1 levels can vary in vivo has recently been
demonstrated by the identification of a common single nu-
cleotide polymorphism (SNP rs2304277) at the 3′ end of
theOGG1 gene that is associated with a lower expression of
the enzyme and that has been linked to an increased ovar-
ian cancer risk in breast cancer patients carrying mutations
in BRCA1 (35). In order to simulate the situation in the
BRCA1-deficient ovarian tumours carrying lower OGG1
amounts, we made use primarily of the human ovarian
carcinoma cell line A2780 (ECACC 93112519), which was
treated with various combinations of siRNAs (Supplemen-
tary Figure S1) and subsequently with olaparib. As shown
in Figure 2A, knock-down of BRCA1 caused a substantial
sensitization of the cells to PARPi treatment in clonogenic
assays, but this hypersensitivity was considerably attenuated
by a simultaneous knock-down of OGG1, despite the fact
that the knock-down of OGG1 alone was slightly toxic to
these cells in the clonogenic assays. Similar results were ob-
tained with human embryonic kidney HEK293 cells (Sup-
plementary Figure S2A).
Quantification of strand breaks by alkaline comet as-
says (Figure 2B) revealed that olaparib treatment increased
the percentage of tail DNA ∼3-fold in the control cells
treated with siRNA against luciferase (siLuc). Knock-down
of BRCA1 caused a ∼13-fold increase in tail DNA percent-
age, but this amountwas reduced almost to levels seen in un-
treated cells when both BRCA1 and OGG1 were knocked
down. This finding was surprising; because cells treated
with both OGG1 and BRCA1 siRNAs were more sensitive
to olaparib treatment than the control siLuc cells, but less
so than cells treatedwith BRCA1 siRNAalone, we expected
the percentage of tailDNA to reflect the results of the clono-
genic assays. This was clearly not the case and, although the
result could be explained by the difference in exposure times
(continuous versus 24 h) in the two assays, we decided to
confirm it by studying the formation of DSBs in the same
cells. As shown in Figure 2C, quantification of  -H2AX
foci by indirect immunofluorescence reflected the results of
the comet assays, with ∼20% of olaparib-treated BRCA1-
depleted cells displaying more than 10  -H2AX foci and
BRCA1/OGG1 doubly depleted cells showing levels close
to untreated background. This suggested that the majority
of DNA breaks bound by PARPs in asynchronous cell pop-
ulations arises through OGG1-catalysed processing of Go.
MYH knock-down also causes partial rescue of olaparib sen-
sitivity in BRCA1-depleted cells
If Go persists in DNA until replication, polymerases  or
ε can insert both C and A opposite (36–38). While OGG1
removes G◦ from Go/C pairs (33,34), it does not address
Go/Amispairs. This is accomplished by theMutY homolog
(MYH orMUTYH), which initiates BER by excising the A
from theGo/Amispair (39). Because BERuses polymerase-
 or -, which insert preferentially a C opposite the Go in
the template strand (40), the repair process restores Go/C
pairs that can then be re-addressed by OGG1 (Figure 1).
However, in contrast to OGG1, MYH is a monofunctional
DNA glycosylase that lacks lyase activity (41). The breaks
generated by AP-endonuclease duringMYH-initiated BER
of Go/A mispairs arising during DNA replication either
through the incorporation of A opposite unrepaired Go
in the template strand or, alternatively, by incorporation
of Go opposite a template A are thus simple nicks, rather
than single nucleotide gaps. We therefore wanted to learn
whether these SSBs were also addressed by PARPs and
whether MYH depletion also attenuated the sensitivity of
the BRCA1 deficient cells to olaparib.
The effect of MYH knock-down (Supplementary Figure
S1) on cell killing (Figure 3A) and the number of DNA
breaks as measured by the comet assay (Figure 3B) or the
number of  -H2AX foci (Figure 3C) were comparable to
those seen with OGG1 downregulation. An analogous res-
cue of cell sensitivity was observed in human embryonic
kidney HEK293 cells (Supplementary Figure S2B). This
shows that the simple nicks generated by the action ofMYH
and AP-endonuclease during the processing of Go/A mis-
pairs are substrates for PARPs, similarly to the single nu-
cleotide gaps generated by OGG1 and AP-endonuclease
during the processing of Go/C mispairs.
In order to ensure that the above-described phenomena
were not caused by some unspecific effect of BER atten-
uation with OGG1- or MYH siRNAs, we knocked-down
RNaseH2A (Fig S3A). RNaseH2 is responsible for incising
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Figure 2. The synthetic lethality of PARP inhibition and BRCA1 deficiency is attenuated by depletion of the 8-oxoguanine DNA glycosylase OGG1. (A)
The hypersensitivity of BRCA1-depleted human ovarian carcinoma cell line A2780 to olaparib treatment as measured by clonogenic assays is partially
rescued by a reduction in the levels of OGG1 (Supplementary Figure S1A and B). The data are normalized to untreated cells and represent a mean of at
least three independent experiments, each carried out in triplicate± s.d.. siLuc, control cells treated with siRNA against luciferase. Asterisks indicate levels
of statistical significance, calculated by Two-Way ANOVA test (P-value < 0.05 *, < 0.01 **, < 0.001 ***, < 0.0001 ****). Significance: siLuc––siBRCA1;
siBRCA1––siBRCA1/siOGG1. (B) OGG1 knock-down attenuates the genotoxicity of olaparib treatment measured by alkaline comet assays. The data
represent a mean of at least three independent experiments, each carried out in triplicate ± s.d.. siLuc, control cells treated with siRNA against luciferase.
Asterisks indicate levels of statistical significance, calculated by Two-Way ANOVA test (P-value < 0.05 *, < 0.01 **, < 0.001 ***, < 0.0001 ****). Sig-
nificance: (siLuc + olaparib) – (siBRCA1 + olaparib); (siBRCA1 + olaparib) – (siBRCA1/siOGG1 + olaparib). (The images for siOGG1 in A and B
were indistinguishable from siLuc and are not shown for reasons of space, but the quantification is shown in green in the graphs.) (C) DNA damage sig-
nalling visualized by  -H2AX phosphorylation in olaprib-treated BRCA1-depleted cells is diminished by a reduction in OGG1 levels. The graph shows
the percentage of cells with more than 10 foci. At least 100 cells were counted in each field. Asterisks indicate levels of statistical significance, calculated by
Two-Way ANOVA test (P-value < 0.05 *, < 0.01 **, < 0.001 ***, < 0.0001 ****). Significance: (siLuc + olaparib) – (siBRCA1 + olaparib); (siBRCA1 +
olaparib) – (siBRCA1/siOGG1 + olaparib).
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Figure 3. The synthetic lethality of PARP inhibition and BRCA1 deficiency is attenuated by depletion of Go/A mismatch-specific adenine glycosylase
MYH. (A) The hypersensitivity of BRCA1-depleted human ovarian carcinoma cell line A2780 to olaparib treatment as measured by clonogenic assays
is partially rescued by a reduction in the levels of MYH (Supplementary Figure S1A and B). The data are normalized to untreated cells and represent a
mean of at least three independent experiments, each carried out in triplicate ± s.d.. siLuc, control cells treated with siRNA against luciferase. Asterisks
indicate levels of statistical significance, calculated by Two-Way ANOVA test (P-value < 0.05 *, < 0.01 **, < 0.001 ***, < 0.0001 ****). Significance:
siLuc––siBRCA1; siBRCA1––siBRCA1/siMYH. (B) MYH knock-down attenuates the genotoxicity of olaparib treatment measured by alkaline comet
assays. The data represent a mean of at least three independent experiments, each carried out in triplicate ± s.d.. siLuc, control cells treated with siRNA
against luciferase. Asterisks indicate levels of statistical significance, calculated by Two-Way ANOVA test (P-value < 0.05 *, < 0.01 **, < 0.001 ***, <
0.0001 ****). Significance: (siLuc + olaparib) – (siBRCA1 + olaparib); (siBRCA1 + olaparib) – (siBRCA1/siMYH+ olaparib). (The images for siMYH in
A and Bwere indistinguishable from siLuc and are not shown for reasons of space, but the quantification is shown in green in the graphs.) (C) DNA damage
signalling visualized by  -H2AX phosphorylation in olaprib-treated BRCA1-depleted cells is diminished by a reduction in MYH levels. The graph shows
the percentage of cells with more than 10 foci. At least 100 cells were counted in each field. Asterisks indicate levels of statistical significance, calculated by
Two-Way ANOVA test (P-value < 0.05 *, < 0.01 **, < 0.001 ***, < 0.0001 ****). Significance: (siLuc + olaparib) – (siBRCA1 + olaparib); (siBRCA1 +
olaparib) – (siBRCA1/siMYH + olaparib).
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DNA at the 5′ side of ribonucleotides misincorporated into
DNA during replication (42). In the absence of RNaseH2,
topoisomearse I incises DNA at the ribose residue to give
rise to PARP-trapping breaks that are highly recombino-
genic (43) and that have recently been shown to sensi-
tize RNaseH2-deficient cells to olaparib (44). As shown
by pulsed-field gel electrophoresis (PFGE, Supplementary
Figure S3B and C), RNaseH2A knock-down gave rise to
a similar amount of DSBs as a knock-down of BRCA1,
and the amount of breaks in DNA of cells in which both
proteins were depleted was additive. As in the comet assays
(Figure 3B), the DSB amount in cells doubly-depleted of
BRCA1 andMYHwas lower than in the siLuc-treated cells
(Supplementary Figure S3B and C). This suggests that the
effects described above are indeed specific to the depletion
of the two oxidation damage-specific enzymes.
Olaparib toxicity in BRCA1-depleted cells is attenuated by
treatments with a ROS scavenger, hypoxia or OGG1 in-
hibitor
We wished to confirm the above phenomena further, with-
out having to resort to the use of OGG1 or MYH siRNAs.
In order to demonstrate that the partial rescue of olaparib
toxicity in BRCA1-depleted cells was indeed linked to the
processing of oxidative DNA damage, we studied the ola-
parib sensitivity in cells treated with the free radical scav-
enger NAC. Similarly to the downregulation of OGG1 and
MYH, NAC treatment also brought about a reduction in
the toxicity of the PARPi in the BRCA1 depleted A2780
cells (Figure 4A) and reduced the number of DNA breaks
as determined by comet assays (Figure 4B). A similar result
was obtained with BRCA1-depleted cells grown under hy-
poxic (1% oxygen) conditions (Figure 4C and Supplemen-
tary Figure S4A), as well as by pre-incubation with the re-
cently described (27) OGG1 inhibitor TH5487 (Figure 4D).
That the cells were indeed grown under hypoxic conditions
is shown by activation of HIF1 in Supplementary Figure
S4A.
Oxygen metabolism modulates the response of BRCA1-
mutated breast cancer cells to olaparib
To address the possibility that the above-described phenom-
ena were a peculiarity of the A2780 ovarian cell line or of
the siRNA treatments, we repeated the OGG1- and MYH
knock-downs (Supplementary Figure S4B) and NAC treat-
ment with the human, BRCA1-mutated breast cancer cell
line SUM149PT. These cells possess only a single BRCA1
allele, which carries a frameshift (2288delT) mutation. The
outcome of these experiments was very similar to those ob-
tained with the A2780 cells: the toxicity of olaparib was
substantially reduced when either glycosylase was depleted
(Figure 4E), or when the cells were treated with NAC (Fig-
ure 4F).
Oxygen metabolism modulates also the response of RAD51-
depleted cells to olaparib
We asked whether the observations described above were
limited to BRCA1-depleted cells, or whether oxygen
metabolism affected the response to olaparib generally in
cells with HR deficiency. We therefore treated the A2780
cells with siRNAs targetting MYH and/or RAD51 (Sup-
plementary Figure S4C). Cells depleted of RAD51, a key
member of the HR pathway, were highly sensitive to ola-
parib as determined by clonogenic assays, whereas MYH-
depleted cells were similarly sensitive to the control, siLuc-
treated cells. However, as in the case of BRCA1/MYH
knock-downs, a combined depletion of MYH and RAD51
desensitized the cells to the PARPi (Figure 5A). The desen-
sitization was reflected in a decrease in the number of DNA
breaks as measured by comet assays (Figure 5B).
Taken together, the above data demonstrate that oxygen
metabolism is a significant contributor to PARPi cytotoxi-
city in cells with HR malfunction.
DISCUSSION
PARP inhibitors represent the first class of cancer
chemotherapeutics that target a genetic defect present solely
in the tumour cells. They therefore have a very wide ther-
apeutic window and the fact that they are generally well-
tolerated helped them gain a rapid approval for clinical
use. Most recently, Federal Drug Administration has ap-
proved olaparib (Lynparza™) for use as maintenance treat-
ment of adult patients with deleterious or suspected dele-
terious germline or somatic BRCA-mutated advanced ep-
ithelial ovarian-, fallopian tube- or primary peritoneal can-
cer, who showed complete or partial response to first-line
platinum-based chemotherapy. However, PARPis might be
effective in the treatment of other tumour types, alone or
in combination with other therapies, and in order to be
able to suggest which tumour types might be sensitive to
PARPi therapy, it is important to know how this class of
drugs works at the molecular level. Moreover, it is impor-
tant to understand the reasons underlying the emerging
threat of therapy resistance, which has to date been linked
to the upregulation of drug efflux pathways, to reactiva-
tion of BRCA1/2 function through secondary genetic al-
terations, inactivation of NHEJ or shieldin, activation of
alternative NHEJ pathways, or inactivation of poly-ADP-
ribose glycohydrolase (PARG), an enzyme that degrades
PAR chains (18). In this work, we uncovered another way
to PARPi resistance in BRCA1-depleted cells: a reduction
in the efficiency of oxidative damage repair. We show that
partial siRNA-mediated knock-down of mRNAs encoding
the DNA glycosylases OGG1 (Figure 2) or MYH (Figure
3) is sufficient to desensitize BRCA1-depleted cells to ola-
parib treatment. We further demonstrate that this effect is
not an artefact of siRNA treatments, as similar effects were
seen upon chemical inhibition of OGG1 or by growing the
cells in the presence of antioxidants or in a hypoxic envi-
ronment (Figure 4). We also show that the effect is not re-
stricted to BRCA1-depleted cells, because knock-down of
RAD51 has similar consequences (Figure 5). We therefore
posit that, under normal circumstances, SSBs associated
with Go processing are rapidly chaperoned to the down-
stream steps of BER, possibly through a direct interaction
of OGG1 and PARP1 (45). If unrepaired, these breaks are
channelled to HR. In cells lacking the latter repair pathway,
they become genotoxic through aberrant processing. When
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Figure 4. The synthetic lethality of PARP inhibition and BRCA1 deficiency is attenuated by the antioxidant NAC, by hypoxia or by OGG1 inhibition.
(A) The hypersensitivity of BRCA1-depleted human ovarian carcinoma cell line A2780 to olaparib as measured by clonogenic assays is partially rescued
by a treatment with the antioxidant NAC. Significance: (−NAC) siLuc - (−NAC) siBRCA1; (−NAC) siBRCA1 - (+NAC) siBRCA1. (B) NAC treatment
attenuates the genotoxicity of olaparib in BRCA1-depleted cells measured by alkaline comet assays. Significance: (−NAC, −olaparib) siBRCA1 - (−NAC,
+ olaparib) siBRCA1; (−NAC, + olaparib) siBRCA1 - (+NAC, +olaparib) siBRCA1. (C) BRCA1-depleted human ovarian carcinoma cell line A2780
grown in hypoxic environment (Supplementary Figure S4A) is desensitized to olaparib, as measured by clonogenic assays. Significance: Normox siLuc
- Normox siBRCA1; Normox siBRCA1 - Hypox siBRCA1; (D) The hypersensitivity of BRCA1-depleted human ovarian carcinoma cell line A2780 to
olaparib as measured by clonogenic assays is partially rescued by a treatment with the OGG1 inhibitor TH5487. Significance: siLuc (−TH5487) – siBRCA1
(−TH5487); siBRCA1 (−TH5487) – siBRCA1 (+TH5487). (E) The hypersensitivity of triple-negative BRCA1-mutated SUM149PT cells to olaparib as
measured by clonogenic assays is partially rescued by pre-treatment with OGG1- or MYH siRNAs (Supplementary Figure S4B). Significance: siLuc –
siOGG1; siLuc – siMYH. (F) The hypersensitivity of triple-negative BRCA1-mutated SUM149PT cells to olaparib as measured by clonogenic assays is
partially rescued by pre-treatment with NAC. Significance: (−NAC) siLuc – (+NAC) siLuc. The results in A–F are means of at least three independent
experiments, each carried out in triplicate ± s.d.. Asterisks indicate levels of statistical significance, calculated by Two-Way ANOVA test (P-value < 0.05
*, < 0.01 **, < 0.001 ***, < 0.0001 ****).
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Figure 5. Depletion ofMYH glycosylase attenuates the sensitivity of RAD51-depleted cells to olaparib treatment. (A) RAD51 and/orMYHwere knocked
down in the ovarian cancer cell line A2780 with siRNAs (Supplementary Figure S4C) and the sensitivity of the cells to olaparib treatment was assayed by
clonogenic assays. Significance: siLuc – siRAD51; siRAD51 – siRAD51/siMYH. (B) Accumulation ofDNAbreaks in the olaparib-treatedRAD51- and/or
MYH-depleted cells was estimated by comet assays. Significance: (siLuc + olaparib) – (siRAD51 + olaparib); (siRAD51 + olaparib) – (siRAD51/siMYH
+ olaparib). (The images for siMYH were indistinguishable from siLuc and are not shown for reasons of space, but the quantification is shown in the
green columns.) The results in A and B are means of at least three independent experiments, each in triplicate ± s.d.. Asterisks indicate levels of statistical
significance, calculated by Two-Way ANOVA test (P-value < 0.05 *, < 0.01 **, < 0.001 ***, < 0.0001 ****).
the number of unrepaired breaks, such as those bound by
inhibited PARP1, is reduced, the cyctotoxicity of PARPis is
similarly attenuated. As shown in this study, SSBs generated
during Go processing represent a significant proportion of
these cytotoxic breaks.
It has ben suggested that there exist two distict path-
ways of BER: one (including oxidative damage repair) that
is PARP1-dependent and the other (including hydrolytic
damage repair) that may not require PARP1 (46). It could
therefore be anticipated that only the subset of SSBs gen-
erated by the PARP1-dependent pathway will contribute to
PARPi toxicity. However, our earlier findings demonstrated
that SSBs generated not only duringGo processing (26), but
also those arising during uracil processing, a BER pathway
postulated to be PARP1-independent, can be seen by mis-
match repair (47). We would therefore argue that all BER-
associated SSBs can potentially be channelled to HR and
thus play a major role in the toxicity of PARPi in HR-
deficient cells.
Our findings are of substantial relevance to the success of
therapy of HR-deficient cancers. They demonstrate that the
decreased efficiency of BER can negatively affect the out-
come of PARPi therapy. Importantly, this reduction in BER
efficiency does not have to be caused by inactivating gene
mutations; a mere downregulation of expression of OGG1
andMYH genes, polymorphisms that affect mRNA or pro-
tein stability, the interaction of the respective enzymes with
their cognate partners, or simply a ROS-poor environment,
are all sufficient to make the cells less sensitive to olaparib
treatment. This knowledge should make it possible to pre-
dict the efficacy of PARPi treatment by an analysis of these
parameters in patient DNA or in tumour biopsies. For ex-
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Figure 6. Heterogeneity of Go staining in tumour tissue. Clear cell renal cell carcinoma immunostained using amonoclonal antibody against Go. The heavy
staining apparent in the peripheral tertiary lymphoid structure containing lymphocytes (white arrows) contrasts with the substantially weaker staining in
the tumour cells (black arrows).
ample, the common polymorphism inOGG1 rs2304277 has
been linked to BRCA1-deficiency in ovarian cancer. The au-
thors of the genetic study (35) anticipated that a decreased
amount of OGG1 in the BRCA1-deficient tumour is likely
to sensitize it to PARPi therapy. We show that the opposite
is true––by not excising G◦ from DNA, the aberrant base
remains and, during replication, can mispair with A to give
rise to G to T transversion mutations characteristic of ox-
idative DNA damage, possibly by exceeding the repair ca-
pacity of MYH. In the long run, this mutagenesis is likely
to spur tumour progression and transformation to malig-
nancy, but its short term outcome would be resistance to
the most promising treatment offered to patients with HR-
deficient tumours. Unfortunately, the therapeutic value of
the above biomarkersmay be limited by tumour heterogene-
ity. Immunohistochemical ananlysis ofGo levels inDNA re-
vealed substantial differences. In the tissue section shown in
Figure 6, tumour-infiltrating lymphocytes and tertiary lym-
phatic structures were very strongly stained. In contrast, tu-
mour cell nuclei were frequently stained rather weakly. It is
thus possible that these cells might survive olaparib treat-
ment.
As discussed above, PARPis are currently used in the
clinic as single agents, but several attempts have been made
to improve their efficacy and overcome drug resistance by
combining their use with another therapeutic drug. A re-
cent report demonstrated that PARPi sensitivity is aug-
mented by the depletion of RNaseH2 (44), which removes
ribonucleotides from genomic DNA (42). Ribonucleotides
that remain inDNA form deleterious adducts with topoiso-
merase I, and processing of these adducts gives rise to DNA
breaks that cause chromosomal rearrangements and that
are highly-toxic to HR-deficient cells (43). There have also
been attempts to combine PARPis with radiation therapy
(48,49). In this scenario, ROS generated by ionizing radia-
tion will cause an increase in the number of DNA breaks
and thus also in the sensitivity of the HR-deficient tumour
cells to PARPis. Unfortunately, our data predict that the ef-
ficacy of PARPi therapy in poorly-oxygenatedHR-deficient
tumours or tumour regions would be diminished due to the
reduced load of oxidative damage and this effect would be
important also during standard radiotherapy, to which hy-
poxic tumours are particularly resistant (50). However, be-
cause protons or carbon ions cause water radiolysis, com-
bined therapy with these sources and PARPis might offer a
way of overcoming this setback.
It is clear that response to PARPis is affected bymany dis-
tinct factors. If we are to achieve better therapeutic efficacy,
we need to understand not only which factors are involved,
but also their interplay and relative importance.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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